Pill for Teens and Adults with Severe Alopecia Areata
Olumiant (baricitinib) — once-daily pill for teens and adults with severe alopecia areata
Medcelerator Brief
This is for families and adults living with severe alopecia areata who are 12 years or older. It explains the US prescribing-information expansion in September 2026 that added adolescents to Olumiant (baricitinib), the EU SmPC adolescent wording, the once-daily oral path through dermatology, and what BRAVE-AA-PEDS showed. It is not an under-12 approval, not a cream, and not a reason to skip infection and lab screening. Authorized is not funded.
Olumiant is an oral Janus kinase (JAK) inhibitor (baricitinib). The United States prescribing information revised 09/2026 expanded the severe alopecia areata indication to adults and pediatric patients 12 years of age and older. The European Union SmPC already authorises the same age band for severe alopecia areata. It is a once-daily tablet (or dispersed tablet when swallowing is hard), not a cream and not a one-time procedure. It is not a cure, not approved under age 12 for this use on the sources used here, and not interchangeable with other JAK inhibitors by brand name. Marketed in the United States by Lilly USA, LLC.
Distinct path — not this use (fact-only): The same brand is also authorised for certain rheumatoid arthritis, hospital COVID-19, and (in the EU) atopic dermatitis and juvenile idiopathic arthritis uses. Those are different diseases and different evidence. Another oral JAK inhibitor, ritlecitinib (Litfulo), is separately approved in the United States for severe alopecia areata from age 12; it is a different molecule and a different label.
Where this is taking place
Commercial doors today: United States (FDA age expansion reflected in the Lilly USPI Revised 09/2026, Recent Major Changes for Indications and Usage 1.3) and the European Union (EMA SmPC §4.1: severe alopecia areata in adult and adolescent patients 12 years of age and older). Company materials also describe prior adolescent authorisation in Japan; Japanese PMDA wording was not retrieved for this article — treat Japan as not confirmed here.
Who gives it: A dermatology or pediatric dermatology clinic that diagnoses severe alopecia areata, screens for infections and labs required on the label, and can prescribe through specialty pharmacy channels already used for adult Olumiant. Suspected side effects in the United States: Lilly 1-800-LillyRx (1-800-545-5979) or FDA MedWatch 1-800-FDA-1088.
Trial that supported the adolescent label: BRAVE-AA-PEDS — NCT05723198 (also called AA-PEDS on the USPI). Phase 3, randomised, double-blind, placebo-controlled. Sponsor: Eli Lilly and Company. Status checked 1 October 2026: recruiting (the adolescent cohort that supported the age line is described on the USPI; the overall study continues toward younger ages). A trial site is not a marketing authorisation in that country.
Outside labelled jurisdictions: Health Canada, MHRA, TGA, Swissmedic, and PMDA authorisation of Olumiant for adolescent severe alopecia areata is not confirmed on sources used here. Do not import on your own.
Approval matrix
| Regulator | Status | Date / source | Notes |
|---|---|---|---|
| FDA (United States) | Approved (expanded indication) | USPI Revised 09/2026 (Recent Major Changes: Indications and Usage, Severe Alopecia Areata 1.3 — 09/2026). Company announcement dated 25 Sep 2026 | Adults and pediatric patients ≥12 with severe alopecia areata. Supplement number on Drugs@FDA not retrieved — not invented. |
| EMA / European Commission | Authorised for adolescents on current SmPC | SmPC §4.1 Alopecia areata (retrieved 1 Oct 2026) | “Adult and adolescent patients 12 years of age and older.” Company materials cite an April 2026 EC adolescent decision; this article relies on the published SmPC text, not the press date alone. |
| Health Canada | Not confirmed for adolescent AA | — | Do not treat a US or EU label as a Canadian Product Monograph for teens. |
| MHRA (UK) | Not confirmed | — | — |
| TGA / PMDA / Swissmedic / other | Not confirmed for this age expansion | — | — |
Access by country
- United States: Ask dermatology whether the person is 12 or older with severe alopecia areata on the USPI. Path: TB and hepatitis screen → baseline blood counts, liver, and kidney checks → once-daily oral tablet (see dose below) → lipid check about 12 weeks after start → ask the plan whether this indication is covered. No list price or copay dollars in this article.
- European Union: Ask a clinician experienced with the condition whether the person matches the SmPC (adolescents ≥12, and for the adolescent AA dose band ≥30 kg). EU starting dose for adolescents differs from the US recommended start — see How it is taken.
- Canada / UK / other countries: Authorisation not confirmed for the adolescent AA use on sources used here.
- If your regulator has not authorised it: do not import on your own.
Who is eligible
United States (prescribing information, indication 1.3 revised 09/2026):
- Indication: Treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older.
- Limitations of use: Not recommended with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.
- Pediatrics: Safety and effectiveness established in patients ≥12. Supported by a controlled trial with 316 pediatric subjects ≥12 weighing at least 30 kg exposed for at least one year (USPI §8.4). Not established under 12 years.
- Before starting (AA): Evaluate active and latent TB; viral hepatitis screening per guidelines; complete blood count (do not start if ALC <500, ANC <1000, or hemoglobin <8 g/dL); baseline hepatic and renal function; update immunizations. Avoid live vaccines with Olumiant.
- Pregnancy and breastfeeding: May cause fetal harm (animal data). Advise effective contraception. Advise not to breastfeed during treatment and for 4 days after the last dose (USPI). Pregnancy registry: 1-800-284-1695 / pregnancyregistry.lilly.com.
European Union (SmPC §4.1–4.2, alopecia areata):
- Severe alopecia areata in adult and adolescent patients 12 years of age and older.
- Adolescent AA dose on the SmPC is for patients weighing ≥30 kg. Safety and efficacy not established under 12 years or under 30 kg for AA.
- Pregnancy is a contraindication on the SmPC (stricter wording than the US label’s risk language). Follow the SmPC and local specialist advice.
Not this indication, on the sources used here:
- Children under 12 for alopecia areata.
- Mild patchy alopecia treated only with topicals when the clinic does not call the disease severe.
- Rheumatoid arthritis, COVID-19, atopic dermatitis, or JIA uses of the same brand.
- Combining with another JAK inhibitor or a biologic immunomodulator for AA.
What the pivotal study showed (BRAVE-AA-PEDS / NCT05723198)
Use the US prescribing information section 14.3 (Table 16) for a US prescription conversation. The EMA SmPC reports the same adolescent trial with closely matching percentages.
Design (USPI): Randomised, double-blind, placebo-controlled 36-week trial in pediatric subjects 12 years and older weighing ≥30 kg with severe alopecia areata. In the placebo-controlled portion, 257 adolescents were randomised to placebo (88), Olumiant 2 mg (83), or Olumiant 4 mg (85). Primary outcome: proportion with SALT ≤20 (about 80% or more scalp hair coverage) at Week 36.
Baseline (USPI): Mean age about 15 years in the adolescent cohort narrative; median SALT 100 (complete or near-complete scalp loss was common).
Result (USPI Table 16, Week 36):
| Endpoint | Placebo | Olumiant 2 mg | Olumiant 4 mg |
|---|---|---|---|
| SALT ≤20 | 5% | 27% | 42% |
| SALT ≤10 | 2% | 21% | 37% |
Response rates were higher when baseline SALT was 50–94 than when baseline SALT was 95–100 (USPI Table 17). Overall safety in adolescents was described as consistent with adults with severe AA; acne and neutropenia were noted more often in adolescents in EU SmPC narrative.
How it is taken
United States (USPI §2.4) — name this jurisdiction when talking to a US clinician:
| Item | On-source detail (USPI) |
|---|---|
| Drug | Olumiant (baricitinib) tablets 1 mg, 2 mg, 4 mg |
| Recommended start (adults and ≥12) | 2 mg once daily orally, with or without food |
| If response not enough | Increase to 4 mg once daily |
| Nearly complete / complete scalp loss (± major eyelash/eyebrow loss) | Consider starting at 4 mg once daily |
| After good response on 4 mg | Reduce to 2 mg once daily |
| Moderate kidney impairment (eGFR 30–<60) | Reduce (see USPI Table 5) |
| Severe kidney impairment (eGFR <30) or severe hepatic impairment | Not recommended for AA |
| Strong OAT3 inhibitor (e.g. probenecid) | Cut the dose in half per USPI Table 6 |
| Cannot swallow tablets | Dispersion / G-tube / NG-tube options in USPI §2.8 |
European Union (SmPC §4.2 adolescents with AA) — different start than the US recommended dose:
- Adolescents ≥12 weighing ≥30 kg: recommended dose 4 mg once daily.
- Consider 2 mg once daily after sustained disease control if eligible for tapering.
- Reassess if no meaningful benefit by 36 weeks.
Do not mix US and EU dose rules without the clinician naming which label they are using.
Safety (what the label puts first)
US boxed warning (JAK class language on the Olumiant USPI):
- Serious infections, including tuberculosis — test and treat latent TB before use (except the separate COVID setting). Interrupt if a serious infection occurs.
- Higher all-cause mortality with another JAK inhibitor versus TNF blockers in older RA patients with cardiovascular risk.
- Malignancies, including lymphoma and lung cancer signals with another JAK inhibitor versus TNF blockers.
- Major adverse cardiovascular events (MACE).
- Thrombosis (DVT, PE, arterial events).
Other USPI warnings that matter for teens: hypersensitivity; gastrointestinal perforation risk; lab abnormalities (neutrophils, lymphocytes, hemoglobin, liver enzymes, lipids); avoid live vaccines; hypoglycemia reports in people with diabetes after JAK inhibitors.
Common AA trial reactions (adults, ≥1% and more than placebo pattern on USPI): upper respiratory infections, headache, acne, lipid increases, CPK increase, urinary tract infection, liver enzyme elevations, folliculitis, and others listed in USPI Table 10. Adolescent safety was described as consistent with adults.
How to talk to a doctor
Bring: age and weight, how long this alopecia episode has lasted, prior treatments tried, infection history (including shingles), clotting or heart history, cancer history, pregnancy plans, current medicines (especially strong immunosuppressants, probenecid, and other JAK or biologic drugs), and which country’s label the clinic follows.
Ask: Do we meet the severe AA definition on the label? Are labs and TB screening done? Is the plan the US 2 mg start or the EU 4 mg adolescent start? What monitoring schedule will we use? What should make us stop or hold the drug? How does this compare with ritlecitinib or other options the clinic uses?
Research and regulatory team (from sources only — no invented contacts)
- Sponsor (trial and US marketer): Eli Lilly and Company / Lilly USA, LLC (USPI; ClinicalTrials.gov NCT05723198).
- EU marketing authorisation holder: Eli Lilly Nederland B.V. (SmPC).
- Named individual principal investigator is not listed as a single PI on the ClinicalTrials.gov record used here (study director contact is Lilly’s trial phone line). Do not invent a clinician name.
Canada zoom: adolescent AA not confirmed
Olumiant for adolescent severe alopecia areata is not confirmed as a Health Canada authorisation on sources used here. A US PI or EU SmPC is not a Canadian Product Monograph. Do not import on your own.
Bottom line
Olumiant is a labelled once-daily oral option for severe alopecia areata in people 12 years and older in the United States (USPI Revised 09/2026) and the European Union (SmPC). In BRAVE-AA-PEDS, about 42% on 4 mg and 27% on 2 mg reached SALT ≤20 at week 36 versus 5% on placebo (USPI Table 16). The near-term path is a dermatology clinic that can run the infection and lab screens and prescribe under the correct country’s dose rules — not a home cure, not an under-12 approval, and not an assumption that a benefit plan will pay.
Primary sources
How do I get this?
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In the European Union, authorisation is not confirmed; see Possible routes below if any are listed.
General resources for further research
General registries and programmes. They are not routes to this treatment; use them to research further.
United States · Trial registry
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/European Union · Trial registry
CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/
Organizations and researchers
- Sponsor
Primary on this article
Lilly USA, LLC
US labelled marketer / USPI marketed-by — Olumiant adolescent AA
Jurisdiction applicants
- Other
Eli Lilly Nederland B.V.
EU MAH (EMA SmPC §7; Utrecht) — Olumiant adolescent AA